The global PET radiopharmaceuticals market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Positron emission tomography (PET) uses small amounts of radioactive materials called radiotracers or radiopharmaceuticals, a special camera and a monitor to analyze organ and tissue functions. By identifying changes at the cellular level, PET can be successful in the detection of the early onset of disease as compared to other imaging tests. The major factor attributable to the market growth includes the growing scope of nuclear medicines owing to sub factors such as the growing prevalence of cancer, cardiac, and neurological ailments. The isotope Mo-99 is an element used in the production of technetium-99m (Tc-99m). Tc-99m is used in research into a multitude of ailments. Roughly 85% of medical imaging in nuclear medicine uses this isotope (Tc-99m). This amounts to 17 million diagnostic procedures per year all over the globe. 

The growing prevalence of cancer and CVD requires an effective diagnostic solution such as PET radiopharmaceuticals. As evident, most of these diseases can be inhibited through early detection and treatment and that is where PET radiopharmaceuticals play a significant role. According to the WHO, annually, 19.3 million new cancer cases are expected to be reported globally by 2025. According to the WHO, globally, 17.9 million individuals died from CVD in 2019, accounting for 32% of the overall deaths globally. This figure is expected to reach 23.3 million by 2030. As PET radiopharmaceuticals play a significant role in disease diagnosis and treatment, the rising prevalence of these diseases is expected to drive the growth of the global PET radiopharmaceuticals market during the forecast period. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  General Electric Co., Cardinal Health, Inc., and Bayer AG, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global PET Radiopharmaceuticals Market Report by Segment

By Type

• F-18

• RU-82

• Others

By Application

• Oncology

• Cardiology

• Neurology

• Others

Global PET Radiopharmaceuticals Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa